Local delivery system of immune modulating drug for unresectable adenocarcinoma: In vitro experimental study and in vivo animal study

Don Haeng Lee, Sung Gwon Kang, Seok Jeong, Chang Jin Yoon, Jung Ah Choi, Ju Nam Byun, Jae Hyung Park, Kyu Back Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The purpose of the study was to evaluate the efficacy and safety of a developed drug delivery system containing OK-432 through in vitro and animal study. An OK-432-impregnated polycarbonate/polyurethane stent membrane was used to develop a drug delivery system (DDS) enabling the locoregional release of OK-432. Polyethyleneglycol was used as a detergent and porosity generator. The stability of OK-432 in solvent, releasing kinetics of drug, and cytotoxicity of the DDS were evaluated. OK-432-impregnated DDS was implanted in mice in which a human adenocarcinoma cell line was injected and grown in their back. Flow cytometry and enzyme-linked immunosorbent assay were used for quantifying the amount of drug. OK-432 exposed to phosphate-buffered saline and OK-432 exposed to N,N-dimethylacetamide showed similar results on dot graphs and histograms. However, OK-432 exposed to tetrahydrofurane showed different dot graphs and histograms, which means that the antigenicity of the drug was changed. The release rate of OK-432 was maintained at a constant level for 6 weeks. The local delivery of OK-432 was found to have an antitumor effect on a human adenocarcinoma cell line in an animal study, but no effect on this cell line in in vitro cell culture. Histologic examination showed minimal inflammatory reaction in surrounding tissue. Our study shows that local treatment using this OK-432 release system is safe and effective in reducing adenocarcinoma in a mouse model.

Original languageEnglish
Pages (from-to)832-837
Number of pages6
JournalCardioVascular and Interventional Radiology
Volume29
Issue number5
DOIs
Publication statusPublished - 2006 Oct 1

Fingerprint

Picibanil
Immune System
Animals
Adenocarcinoma
Pharmaceutical Preparations
Drug Delivery Systems
polycarbonate
Cells
Cell Line
In Vitro Techniques
Immunosorbents
Stents
Polyurethanes
Flow cytometry
Porosity
Cytotoxicity
Cell culture
Detergents
Assays
Flow Cytometry

Keywords

  • Adenocarcinoma
  • Drug delivery
  • Gastrointestinal tract
  • OK-432
  • Sustainable release

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Local delivery system of immune modulating drug for unresectable adenocarcinoma : In vitro experimental study and in vivo animal study. / Lee, Don Haeng; Kang, Sung Gwon; Jeong, Seok; Yoon, Chang Jin; Choi, Jung Ah; Byun, Ju Nam; Park, Jae Hyung; Lee, Kyu Back.

In: CardioVascular and Interventional Radiology, Vol. 29, No. 5, 01.10.2006, p. 832-837.

Research output: Contribution to journalArticle

Lee, Don Haeng ; Kang, Sung Gwon ; Jeong, Seok ; Yoon, Chang Jin ; Choi, Jung Ah ; Byun, Ju Nam ; Park, Jae Hyung ; Lee, Kyu Back. / Local delivery system of immune modulating drug for unresectable adenocarcinoma : In vitro experimental study and in vivo animal study. In: CardioVascular and Interventional Radiology. 2006 ; Vol. 29, No. 5. pp. 832-837.
@article{25e1ec58f09c45d3ab65c68a22305db1,
title = "Local delivery system of immune modulating drug for unresectable adenocarcinoma: In vitro experimental study and in vivo animal study",
abstract = "The purpose of the study was to evaluate the efficacy and safety of a developed drug delivery system containing OK-432 through in vitro and animal study. An OK-432-impregnated polycarbonate/polyurethane stent membrane was used to develop a drug delivery system (DDS) enabling the locoregional release of OK-432. Polyethyleneglycol was used as a detergent and porosity generator. The stability of OK-432 in solvent, releasing kinetics of drug, and cytotoxicity of the DDS were evaluated. OK-432-impregnated DDS was implanted in mice in which a human adenocarcinoma cell line was injected and grown in their back. Flow cytometry and enzyme-linked immunosorbent assay were used for quantifying the amount of drug. OK-432 exposed to phosphate-buffered saline and OK-432 exposed to N,N-dimethylacetamide showed similar results on dot graphs and histograms. However, OK-432 exposed to tetrahydrofurane showed different dot graphs and histograms, which means that the antigenicity of the drug was changed. The release rate of OK-432 was maintained at a constant level for 6 weeks. The local delivery of OK-432 was found to have an antitumor effect on a human adenocarcinoma cell line in an animal study, but no effect on this cell line in in vitro cell culture. Histologic examination showed minimal inflammatory reaction in surrounding tissue. Our study shows that local treatment using this OK-432 release system is safe and effective in reducing adenocarcinoma in a mouse model.",
keywords = "Adenocarcinoma, Drug delivery, Gastrointestinal tract, OK-432, Sustainable release",
author = "Lee, {Don Haeng} and Kang, {Sung Gwon} and Seok Jeong and Yoon, {Chang Jin} and Choi, {Jung Ah} and Byun, {Ju Nam} and Park, {Jae Hyung} and Lee, {Kyu Back}",
year = "2006",
month = "10",
day = "1",
doi = "10.1007/s00270-005-0194-x",
language = "English",
volume = "29",
pages = "832--837",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - Local delivery system of immune modulating drug for unresectable adenocarcinoma

T2 - In vitro experimental study and in vivo animal study

AU - Lee, Don Haeng

AU - Kang, Sung Gwon

AU - Jeong, Seok

AU - Yoon, Chang Jin

AU - Choi, Jung Ah

AU - Byun, Ju Nam

AU - Park, Jae Hyung

AU - Lee, Kyu Back

PY - 2006/10/1

Y1 - 2006/10/1

N2 - The purpose of the study was to evaluate the efficacy and safety of a developed drug delivery system containing OK-432 through in vitro and animal study. An OK-432-impregnated polycarbonate/polyurethane stent membrane was used to develop a drug delivery system (DDS) enabling the locoregional release of OK-432. Polyethyleneglycol was used as a detergent and porosity generator. The stability of OK-432 in solvent, releasing kinetics of drug, and cytotoxicity of the DDS were evaluated. OK-432-impregnated DDS was implanted in mice in which a human adenocarcinoma cell line was injected and grown in their back. Flow cytometry and enzyme-linked immunosorbent assay were used for quantifying the amount of drug. OK-432 exposed to phosphate-buffered saline and OK-432 exposed to N,N-dimethylacetamide showed similar results on dot graphs and histograms. However, OK-432 exposed to tetrahydrofurane showed different dot graphs and histograms, which means that the antigenicity of the drug was changed. The release rate of OK-432 was maintained at a constant level for 6 weeks. The local delivery of OK-432 was found to have an antitumor effect on a human adenocarcinoma cell line in an animal study, but no effect on this cell line in in vitro cell culture. Histologic examination showed minimal inflammatory reaction in surrounding tissue. Our study shows that local treatment using this OK-432 release system is safe and effective in reducing adenocarcinoma in a mouse model.

AB - The purpose of the study was to evaluate the efficacy and safety of a developed drug delivery system containing OK-432 through in vitro and animal study. An OK-432-impregnated polycarbonate/polyurethane stent membrane was used to develop a drug delivery system (DDS) enabling the locoregional release of OK-432. Polyethyleneglycol was used as a detergent and porosity generator. The stability of OK-432 in solvent, releasing kinetics of drug, and cytotoxicity of the DDS were evaluated. OK-432-impregnated DDS was implanted in mice in which a human adenocarcinoma cell line was injected and grown in their back. Flow cytometry and enzyme-linked immunosorbent assay were used for quantifying the amount of drug. OK-432 exposed to phosphate-buffered saline and OK-432 exposed to N,N-dimethylacetamide showed similar results on dot graphs and histograms. However, OK-432 exposed to tetrahydrofurane showed different dot graphs and histograms, which means that the antigenicity of the drug was changed. The release rate of OK-432 was maintained at a constant level for 6 weeks. The local delivery of OK-432 was found to have an antitumor effect on a human adenocarcinoma cell line in an animal study, but no effect on this cell line in in vitro cell culture. Histologic examination showed minimal inflammatory reaction in surrounding tissue. Our study shows that local treatment using this OK-432 release system is safe and effective in reducing adenocarcinoma in a mouse model.

KW - Adenocarcinoma

KW - Drug delivery

KW - Gastrointestinal tract

KW - OK-432

KW - Sustainable release

UR - http://www.scopus.com/inward/record.url?scp=33746425810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746425810&partnerID=8YFLogxK

U2 - 10.1007/s00270-005-0194-x

DO - 10.1007/s00270-005-0194-x

M3 - Article

C2 - 16779692

AN - SCOPUS:33746425810

VL - 29

SP - 832

EP - 837

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 5

ER -